Prostate Cancer Genetic Factors: Genetic Testing & Early Detection
Updated: Oct 2
Written by Dr. Zack Ferris in TheSkyMeds Editorial Standards
Medically reviewed by Jonathan Reed, Medical Content Reviewer Jul 1 2023
Prostate cancer genetic factors can influence who develops the disease, how early it appears, and in some cases how aggressively it behaves. Most prostate cancers are not caused by a single inherited gene change, but certain pathogenic variants—especially in genes such as BRCA2—can substantially increase risk. A strong family history of prostate cancer or related cancers such as breast, ovarian, pancreatic, or colorectal cancer may also provide an imprtant clue to inherited risk. Genetic testing can help identify some of these inherited variants, but it is not itself a test for diagnosing prostate cancer. Early detection still usually involves prostate-specific antigen (PSA) testing and, when indicated, additional assessment such as prostate MRI or biopsy. This guide explains the major genetic factors, who may benefit from genetic testing, and how genetic information can influence conversations about earlier or more intensive prostate cancer screening.
How Do Prostate Cancer Genetic Factors Affect Your Risk?
Genetics can affect prostate cancer risk in two main ways: through inherited gene variants passed through families and through genetic changes that arise only inside a prostate tumor. For someone who has not been diagnosed with prostate cancer, inherited—or germline—risk is the more relevant issue when discussing prevention and early detection.
Family history is an important clue, but it is not the same as having a known inherited mutation. NCI reports that studies have found men with a first-degree relative such as a father, brother, or son with prostate cancer have a higher risk than men without such a history.
Cancer patterns elsewhere in the family matter too. Breast, ovarian, pancreatic, colorectal, endometrial, and prostate cancers can sometimes appear together because certain inherited cancer syndromes affect more than one organ. Family history should therefore be considered on both your mother's and father's sides.
A family history does not prove that a harmful inherited variant is present. Families can share cancer risk for many reasons, including combinations of common genetic variants, environmental factors, aging, and chance.
Which Genes Are Linked to Hereditary Prostate Cancer?
Several genes have been associated with inherited prostate cancer susceptibility, but they do not all carry the same level of risk. BRCA2 has some of the strongest evidence and is particularly important because prostate cancers arising in BRCA2 carriers may be diagnosed younger and may have more aggressive characteristics.
The NCI Genetics of Prostate Cancer resource describes inherited prostate cancer genes including BRCA1, BRCA2, HOXB13, ATM, CHEK2, and mismatch-repair genes involved in Lynch syndrome.
Gene or gene group | Why it matters | Practical meaning |
BRCA2 | Strongly associated with increased prostate cancer risk and more aggressive disease features | Carriers may be advised to discuss PSA screening at a younger age |
BRCA1 | Associated with prostate cancer risk, although the link is generally less pronounced than for BRCA2 | May influence screening and genetic counseling decisions |
HOXB13 | Certain variants, especially G84E, are associated with hereditary and earlier-onset prostate cancer | Particularly relevant when prostate cancer appears repeatedly or at younger ages in a family |
Lynch syndrome genes: MLH1, MSH2, MSH6, PMS2 and EPCAM | Some mismatch-repair gene variants are associated with increased prostate cancer risk as part of Lynch syndrome | Family histories may also include colorectal, endometrial and other Lynch-associated cancers |
ATM, CHEK2, PALB2 and other DNA-repair genes | Some pathogenic variants have been associated with prostate cancer or are included on hereditary cancer panels | The strength of evidence and clinical implications vary by gene and individual variant |
Having one of these variants does not mean prostate cancer is inevitable. It means risk may be higher than average and that screening decisions may need to be individualized.
A genetic test does not answer the question “Do I have prostate cancer?” It answers a different question: “Do I carry an inherited genetic change that may increase my cancer risk or affect how my cancer should be managed?”
Who Should Consider Genetic Testing for Prostate Cancer Risk?
Genetic testing is most useful when personal or family history suggests that an inherited cancer syndrome may be present. It is not automatically necessary for every man simply because prostate cancer is common.
The NCI genetic testing for inherited cancer risk guidance recommends considering genetic counseling when there is a known harmful variant in the family, cancer occurring unusually young, several relatives with related cancers, or other patterns suggesting hereditary cancer. NCI also notes that guidelines recommend germline testing for people with metastatic prostate cancer.
Reasons to discuss genetic testing can include:
A father, brother, son, or several close relatives with prostate cancer, particularly at younger ages.
Several relatives with prostate, breast, ovarian, pancreatic, colorectal, or endometrial cancers.
A known BRCA1, BRCA2, Lynch syndrome, or other cancer-predisposition variant in the family.
Prostate cancer that is metastatic, high-risk, or has particular pathological features for which germline testing is recommended or considered.
A tumor test that detects a variant that could also be inherited.
European Association of Urology guidance recommends germline testing for men with prostate cancer who have a family history of high-risk germline mutations or multiple cancers on the same side of the family, and advises testing when BRCA mutations are identified through tumor testing.
Whenever possible, hereditary cancer testing often begins with a family member who has already developed cancer. That approach can make the results easier to interpret because doctors can first determine whether an identifiable pathogenic variant is present in the affected relative.
What Is the Difference Between Germline and Tumor Genetic Testing?
Germline testing looks for inherited DNA changes present throughout your body, while tumor testing looks for genetic changes within the cancer itself. These tests can overlap, but they answer different clinical questions.
The NCI inherited cancer genetic testing guidance explains that germline testing is commonly performed using blood or saliva. Tumor testing—also called somatic or biomarker testing—examines cancer tissue or, in some settings, tumor-derived material in blood.
Feature | Germline testing | Tumor or somatic testing |
What is tested? | Usually blood or saliva | Cancer tissue or other tumor-derived material |
What does it look for? | Genetic variants inherited from a parent | Genetic changes present in the cancer |
Can the result affect relatives? | Yes, because an inherited variant may also be present in blood relatives | Usually not directly, although some tumor findings can suggest an inherited variant |
Can it help with early detection? | Yes, by identifying people who may need earlier or more individualized screening | Usually used after cancer develops, particularly to help guide treatment |
Can it guide prostate cancer treatment? | Sometimes | Yes, particularly in advanced disease where specific biomarkers may influence therapy |
Does a negative result eliminate cancer risk? | No | No |
A tumor finding can occasionally suggest that a variant may also be present in the germline. When that happens, confirmatory germline testing may be recommended rather than assuming the tumor result is inherited.
Direct-to-consumer genetic tests also require caution. Many consumer tests examine only selected variants rather than comprehensively assessing all clinically relevant changes in a gene, so a reassuring result should not override a concerning family history.
Can Genetic Testing Help With Early Prostate Cancer Detection?
Yes, genetic information can help identify some men who may benefit from discussing PSA screening earlier than average, but a genetic test does not replace prostate cancer screening. PSA remains the main blood test used for early detection.
The European Association of Urology's prostate cancer early-detection guidance recommends offering early PSA testing to well-informed men at increased risk, including men carrying BRCA2 variants from age 40. It lists age 45 for men with a family history of prostate cancer and age 50 for men without those additional risk factors.
Other professional organizations use somewhat different age ranges and intervals, so screening should not be reduced to a universal birthday or single PSA number. NCI summarizes recommendations from several organizations and notes that men with germline pathogenic variants or strong family histories may begin shared decision-making about screening earlier than average.
What does PSA testing tell you?
PSA is a protein produced by the prostate. A higher PSA level can occur with prostate cancer, but it can also rise because of benign prostate enlargement, inflammation, infection, and other factors.
An abnormal PSA therefore does not diagnose cancer. Depending on the result and overall risk, a clinician may repeat the PSA, assess PSA trends, use a validated risk calculator, request prostate MRI, or recommend further investigation.
Where does prostate MRI fit?
MRI can help determine whether suspicious areas are present in the prostate and whether a biopsy may be needed. Current EAU guidance recommends prostate MRI as one of the major tools for evaluating men with certain elevated PSA results before biopsy decisions are made.
Genetic risk, PSA, age, family history, previous test results, and imaging can therefore work together rather than being viewed as competing tests.
Why is shared decision-making important?
Prostate cancer screening has potential benefits and harms. Screening can find clinically significant cancers before they spread, but it can also detect slow-growing cancers that may never have caused symptoms or shortened life.
The CDC prostate cancer screening guidance recommends discussing personal risk, overall health, and the possible benefits and harms of PSA screening with a doctor before testing.
What Happens If a Genetic Test Finds a Variant?
The next step depends on whether the result is pathogenic, negative, or a variant of uncertain significance. A genetic result should therefore be interpreted in the context of your family history rather than read as a simple positive-or-negative cancer answer.
A pathogenic or likely pathogenic variant
A pathogenic variant means there is sufficient evidence that the genetic change is associated with increased disease risk. Depending on the gene, this may influence how early prostate screening begins, how frequently it occurs, and what other cancer risks need to be discussed.
For someone who already has prostate cancer, a pathogenic variant may sometimes influence treatment choices, particularly in advanced disease. It can also have implications for blood relatives.
A negative result
A negative result does not always mean inherited risk has disappeared. If a known family variant has been tested and you do not carry it, the result can be highly informative.
But if no harmful family variant has ever been identified, a negative panel can be “uninformative.” Your age, family history, ancestry, and other clinical risk factors may still justify an individualized screening plan.
A variant of uncertain significance
A variant of uncertain significance, or VUS, means a genetic change has been found but scientists do not yet know whether it affects cancer risk. NCI advises that a VUS is generally not used by itself to make medical management decisions because many are eventually reclassified as benign.
This is one reason professional interpretation matters. A VUS should not be treated as though it were a confirmed harmful BRCA or Lynch syndrome variant.
When Should You Speak to a Doctor or Genetic Counselor?
Consider discussing inherited prostate cancer risk before symptoms develop if several close relatives have had prostate cancer, a relative developed it unusually young, or your family includes breast, ovarian, pancreatic, colorectal, endometrial, or related cancers. A known cancer-predisposition variant in the family is another strong reason to seek guidance.
If you already have prostate cancer, ask whether germline or tumor testing is relevant to your stage, pathology, treatment options, and family history. Guidelines particularly emphasize testing in metastatic disease and selected high-risk situations.
Before an appointment, try to collect a three-generation family cancer history. Record which relatives had cancer, the type of cancer, and approximately how old they were when diagnosed.
A genetic counselor or clinician experienced in cancer genetics can explain what a test can and cannot tell you, which genes are appropriate to test, and what the result may mean for your relatives.
Conclusion
Understanding prostate cancer genetic factors can help identify people whose risk may be higher than average and who may benefit from genetic counseling or earlier discussions about PSA screening. BRCA2 is particularly important, while HOXB13, Lynch syndrome genes, ATM, and several other DNA-repair genes may also contribute to inherited risk.
Genetic testing does not diagnose prostate cancer, and a negative result does not automatically eliminate risk. If prostate or related cancers run in your family, discuss your family history with a healthcare professional or genetic counselor and develop an individualized early-detection plan rather than relying on a consumer genetic test alone.
Frequently Asked Questions
1 . Is prostate cancer hereditary?
Some prostate cancers have an inherited component, but most are not caused by one identifiable inherited mutation. A strong family history or pathogenic variants such as BRCA2 can increase risk. Genetic counseling can help determine whether your family pattern suggests hereditary cancer.
2 . Does BRCA2 increase prostate cancer risk?
Yes. Harmful inherited BRCA2 variants are associated with increased prostate cancer risk and with more aggressive disease characteristics. Men who carry BRCA2 variants may therefore be advised to discuss PSA screening earlier than average.
3 . At what age should someone with a BRCA2 mutation start prostate screening?
The EAU recommends offering PSA testing from age 40 to well-informed men carrying BRCA2 mutations. Other organizations may use slightly different recommendations, so the exact screening schedule should be individualized with a clinician.
4 . Can a genetic blood test detect prostate cancer?
No. Germline genetic testing looks for inherited variants that may increase cancer risk; it does not determine whether prostate cancer is currently present. Early-detection evaluation usually begins with PSA testing and may involve MRI or biopsy when clinically indicated.
5 . Should I get genetic testing if my father had prostate cancer?
Not automatically, but your father's diagnosis is important to discuss with a clinician. Testing becomes more relevant when prostate cancer occurred young, several relatives are affected, or the family also includes cancers such as breast, ovarian, pancreatic, or colorectal cancer.
6 . What does a VUS mean on a genetic test?
A variant of uncertain significance means scientists do not yet know whether that DNA change increases cancer risk. A VUS generally should not be treated like a harmful mutation or used alone to change medical management. Family history and established risk factors remain important.
Comments